Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

ObjectiveHormone receptor (HR)-low/HER2-negative breast cancers (BCs) are more likely to be basal-like BCs, with similar molecular features and gene expression profiles to HR-negative (estrogen receptor <1% or negative and progesterone receptor <1% or negative) BCs. Recently, with the...

Full description

Bibliographic Details
Main Authors: Jing Peng, Yue Hong, Qitong Chen, Feng Xu, Danhua Zhang, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Qian Long, Liqiu Liao, Mingwen Liu, Xuan Liu, Shouman Wang, Wenjun Yi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Endocrinology
Subjects:
breast cancer
estrogen receptor
progesterone receptor
triple-negative breast cancer
HR-low/HER2-negative breast cancer
neoadjuvant chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1347762/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1347762/full

Similar Items